低分子肝素钠治疗慢性阻塞性肺疾病合并呼吸衰竭的临床疗效

Clinical effect of low molecular weight heparin sodium on chronic obstructive pulmonary disease complicated with respiratory failure

下载PDF

导出

摘要目的探讨低分子肝素钠治疗慢性阻塞性肺疾病合并呼吸衰竭的临床疗效。方法选取2018年2月至2021年2月本院收治的60例慢性阻塞性肺疾病合并呼吸衰竭患者作为研究对象,随机分为研究组与对照组,每组30例。对照组给予常规治疗,研究组在对照组基础上给予低分子肝素钠治疗,比较临床疗效、症状缓解时间、住院时间、不良反应发生情况、肺功能[第1秒用力呼气容积(FEV1)、呼气流量峰值(PEF)、第1秒用力呼气容积占用力肺活量的比值(FEV1/FVC)]、慢阻肺患者自我评估测试(CAT)评分、呼吸衰竭症状评及急性加重次数。结果研究组治疗有效率为90.00%,明显高于对照组的63.33%,差异有统计学意义(P<0.05)。研究组不良反应发生率为3.33%,明显低于对照组的46.67%,差异有统计学意义(P<0.05)。研究组症状缓解时间、住院时间均短于对照组,差异有统计学意义(P<0.05)。治疗后,两组FEV1均大于治疗前,PEF、FEV1/FVC均高于治疗前,且研究组FEV1均大于对照组,PEF、FEV1/FVC均高对照组,差异有统计学意义(P<0.05)。治疗后,两组CAT评分、呼吸衰竭症状评分均低于治疗前,急性加重次数均少于治疗前,且研究组慢阻肺症状评分、呼吸衰竭症状评分均低于对照组,急性加重次数少于对照组,差异有统计学意义(P<0.05)。结论低分子肝素钠治疗慢性阻塞性肺疾病合并呼吸衰竭疗效显著,可加快机体恢复,改善肺功能指标,有效缓解症状,减少急性加重次数,安全性较高,值得临床推广应用。 Objective To investigate the clinical efficacy of low molecular weight heparin sodium in the treatment of chronic obstructive pulmonary disease complicated with respiratory failure.Methods 60 patients with chronic obstructive pulmonary disease complicated with respiratory failure admitted to our hospital from February 2018 to February 2021 were selected as the research subjects,and they were randomly divided into the study group and control group,with 30 cases in each group.The control group was given conventional treatment,and the study group was treated with low molecular weight heparin sodium on the basis of the control group,the clinical efficacy,symptom relief time,hospital stay,incidence of adverse reactions,pulmonary function(forced expiratory volume in one second[FEV1],peak expiratory flow[PEF],the ratio of forced expiratory vol-ume in one second to forced vital capacity[FEV1/FVC]),COPD assessment test(CAT),respiratory failure symptom score and the number of acute exacerbations were compared.Results The effective rate in the study group was 90.00%,which was significantly higher than 63.33%in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the study group was 3.33%,which was significantly lower than 46.67%in the control group,and the difference was statistically significant(P<0.05).The symptom relief time and hospital stay in the study group were shorter than those in the control group,and the differences were statistically significant(P<0.05).After treatment,FEV1,PEF and FEV1/FVC in the two groups were higher than those before treatment,and FEV1 in the study group was higher than that in the control group,PEF and FEV1/FVC were higher than those in the control group,the differences were statistically significant(P<0.05).After treatment,the CAT score and respiratory failure symptom score in the two groups were lower than those before treatment,and the number in acute exacerbations was less than that before treatment,and the COPD symptom score

作者陈爽张哲杨圣强 CHEN Shuang;ZHANG Zhe;YANG Shengqiang(Department of Critical Care Medicine,Shanxian Central Hospital,Heze,Shandong,274300,China)

机构地区单县中心医院重症医学科

出处《当代医学》 2022年第34期67-70,共4页 Contemporary Medicine

关键词慢性阻塞性肺疾病低分子肝素钠呼吸衰竭临床疗效 Chronic obstructive pulmonary disease Low molecular weight heparin sodium Respiratory failure Clinical effect

分类号 R56 [医药卫生—呼吸系统]